What are Kalaris Therapeutics, Inc. Common Stock's total assets?

Kalaris Therapeutics, Inc. Common Stock (KLRS) holds $109.8M in total assets, up 6.5% year over year.

How much debt does Kalaris Therapeutics, Inc. Common Stock have?

Kalaris Therapeutics, Inc. Common Stock carries $1.4M in total debt against $68.6M of shareholders' equity, a debt-to-equity ratio of 0.02.

How much cash does Kalaris Therapeutics, Inc. Common Stock have?

Kalaris Therapeutics, Inc. Common Stock holds $34.4M in cash and equivalents.

Can Kalaris Therapeutics, Inc. Common Stock cover its short-term obligations?

Its current ratio is 12.19 — current assets exceed current liabilities.

Where does Kalaris Therapeutics, Inc. Common Stock's balance sheet data come from?

Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Kalaris Therapeutics, Inc. Common Stock KLRS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$34.43M-65.9%	$98.05M+5,883%	$42.39M+2,116%	$88.43M+1,317%	$100.97M+1,832%
Short-term investments	$62.79M—	$19.93M—	$34.61M+593%	——	——
Restricted cash	$500K0.0%	$499K—	$500K—	$500K-9.7%	$500K-9.7%
Prepaid expenses and other current assets	$861K-29.3%	$827K-14.5%	$1.18M+89.1%	$3.23M+1,302%	$1.22M+57.8%
Total current assets	$98.47M-3.6%	$118.81M+4,459%	$78.18M-36.2%	$91.65M-29.5%	$102.18M-27.8%
Operating lease right-of-use assets	$1.43M—	$1.48M—	$1.52M—	——	——
Other non-current assets	$1.75M+328%	$953K+132%	$976K—	$691K—	$410K—
Total assets	$109.81M+6.5%	$121.74M+1,876%	$81.18M-33.8%	$92.84M-29.1%	$103.09M-28.5%
Accounts payable	$905K-61.9%	$1.28M-17.9%	$494K+869%	$3.68M+3,245%	$2.37M+210%
Operating lease liabilities, current	$317K—	$316K—	$376K—	——	——
Total current liabilities	$8.08M+13.1%	$9.71M-60.7%	$6.07M+330%	$7.65M+224%	$7.14M-6.7%
Operating lease liabilities, non-current	$1.09M—	$1.13M—	$1.17M—	——	——
Operating Lease Liabilities (Total)	$1.41M—	$1.45M—	$1.55M—	——	——
Total liabilities	$41.25M+5.2%	$42.92M-24.4%	$39.31M+2,684%	$39.73M+271%	$39.22M+65.5%
Common stock	$2K0.0%	$2K—	$2K-81.8%	$2K-81.8%	$2K-81.8%
Additional paid-in capital	$239.46M+25.6%	$238.81M+1,097%	$191.86M-76.5%	$191.22M-76.5%	$190.63M-76.4%
Retained earnings	-$170.86M-34.8%	-$160M-37.3%	-$150M+78.5%	-$138.11M+80.1%	-$126.76M+81.5%
Accumulated other comprehensive income (loss)	-$49K—	$6K—	$6K+104%	——	——
Total stockholders' equity	$68.56M+7.3%	$78.81M+182%	$41.87M+147%	$53.12M+203%	$63.87M+234%
Total liabilities and stockholders' equity	$109.81M+6.5%	$121.74M+1,876%	$81.18M-33.8%	$92.84M-29.1%	$103.09M-28.5%
Deferred Tax Assets and Other Non-Current Assets	$1.75M+328%	$953K+132%	$976K—	$691K—	$410K—
Net Investment in Lease	$1.43M—	$1.48M—	$1.52M—	——	——
Operating lease right-of-use assets	$1.43M—	$1.48M—	$1.52M—	——	——
Other non-current assets	$1.75M+328%	$953K+132%	$976K—	$691K—	$410K—
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$62.79M—	$19.93M—	$34.61M+593%	——	——
Operating Lease Right-of-Use Assets in Other Assets	$1.43M—	$1.48M—	$1.52M—	——	——
Software and Technology Licenses, Net	$1.75M+328%	$953K+132%	$976K—	$691K—	$410K—
Accrued Expenses And Other Current Liabilities	$6.86M+173%	$8.12M+270%	$5.2M—	$3.97M—	$2.51M—
Royalty Obligation Due To Related Party Noncurrent	$32.08M0.0%	$32.08M0.0%	$32.08M—	$32.08M—	$32.08M—
Total debt	$1.41M—	$1.45M—	$1.55M—	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2K0.0%	$2K—	$2K-81.8%	$2K-81.8%	$2K-81.8%
Other contract costs	$389K—	$0—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Kalaris Therapeutics, Inc. Common Stock's total assets?: Kalaris Therapeutics, Inc. Common Stock (KLRS) holds $109.8M in total assets, up 6.5% year over year.
How much debt does Kalaris Therapeutics, Inc. Common Stock have?: Kalaris Therapeutics, Inc. Common Stock carries $1.4M in total debt against $68.6M of shareholders' equity, a debt-to-equity ratio of 0.02.
How much cash does Kalaris Therapeutics, Inc. Common Stock have?: Kalaris Therapeutics, Inc. Common Stock holds $34.4M in cash and equivalents.
Can Kalaris Therapeutics, Inc. Common Stock cover its short-term obligations?: Its current ratio is 12.19 — current assets exceed current liabilities.
Where does Kalaris Therapeutics, Inc. Common Stock's balance sheet data come from?: Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.